Soros Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Soros Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-250,000	Closed	-$3.85M	–	194
2018 Q4	$3.85M	Hold	250,000	–	–	0.12%	113
2018 Q3	$5.38M	Hold	250,000	–	–	0.12%	123
2018 Q2	$6.08M	Hold	250,000	–	–	0.1%	145
2018 Q1	$4.27M	Sell	250,000 -940,000	-79%	-$18.4M	0.07%	176
2017 Q4	$22.6M	Hold	1,190,000	–	–	0.52%	49
2017 Q3	$20.9M	Buy	1,190,000 +590,000	+98%	+$13.3M	0.5%	43
2017 Q2	$19.9M	Hold	600,000	–	–	0.35%	52
2017 Q1	$19.3M	Buy	+600,000	New	+$20.5M	0.39%	51

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soros Fund Management's TEVA Position: Q4 2018 in Review

Soros Fund Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 160,000 shares — an estimated $3.28M sold.

Soros Fund Management first reported a position in TEVA in Q3 2013 and held it in 9 quarters. The position peaked at $545M in Q1 2014. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

Soros Fund Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Soros Fund Management sold 160,000 Teva Pharmaceuticals shares in Q4 2018, an estimated $3.28M.
Soros Fund Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 9 quarters.
Soros Fund Management's Teva Pharmaceuticals position peaked at $545M in Q1 2014.
551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Soros Fund Management's 13F filing for Q4 2018, filed 14 Feb 2019.